Putative L-asparaginase precursor
Putative L-asparaginase precursor Brand names, Putative L-asparaginase precursor Analogs
Putative L-asparaginase precursor Brand Names Mixture
- No information avaliable
Putative L-asparaginase precursor Chemical_Formula
C1377H2208N382O442S17
Putative L-asparaginase precursor RX_link
http://www.rxlist.com/cgi/generic3/asparaginase.htm
Putative L-asparaginase precursor fda sheet
Putative L-asparaginase precursor msds (material safety sheet)
Putative L-asparaginase precursor Synthesis Reference
No information avaliable
Putative L-asparaginase precursor Molecular Weight
31731.9
Putative L-asparaginase precursor Melting Point
No information avaliable
Putative L-asparaginase precursor H2O Solubility
No information avaliable
Putative L-asparaginase precursor State
Liquid
Putative L-asparaginase precursor LogP
0.059
Putative L-asparaginase precursor Dosage Forms
Powder for solution; Solution (IV or IM injection)
Putative L-asparaginase precursor Indication
For treatment of acute lympocytic leukemia and non-Hodgkins lymphoma
Putative L-asparaginase precursor Pharmacology
In a significant number of patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Elspar exploits a metabolic defect in asparagine synthesis of some malignant cells.
Putative L-asparaginase precursor Absorption
No information avaliable
Putative L-asparaginase precursor side effects and Toxicity
No information avaliable
Putative L-asparaginase precursor Patient Information
No information avaliable
Putative L-asparaginase precursor Organisms Affected
Humans and other mammals
